【摘要】 目的:基于前期对重庆农村地区幽门螺杆菌（Hp）的耐药情况和CYP2C19基因多态性调查,筛选出优化的治疗方案,观察对Hp的根除效果及安全性,为重庆农村地区选择合适的抗Hp治疗方案提供理论依据。方法:选取2015年6月至2016年1月Hp阳性农村患者270例,按照不同治疗方案随机分为3组各90例:A组采用雷贝拉唑0.02 g/埃索美拉唑0.02 g+呋喃唑酮0.10 g+铋剂0.20 g+阿莫西林1.0 g方案;B组采用兰索拉唑0.03 g/泮托拉唑0.04 g+呋喃唑酮0.10 g+铋剂0.20 g+阿莫西林1.0 g方案;C组采用雷贝拉唑0.02 g/埃索美拉唑0.02 g+克拉霉素0.50 g+阿莫西林1.0 g方案。均每天给药2次,连续治疗14 d,治疗结束后4周行¹³C/¹⁴C-尿素呼气试验并比较3组患者的Hp根除率、临床症状缓解情况及不良反应。结果:A与C组的根除率差异有统计学意义[按意向治疗（ITT）分析,χ²=7.273,P=0.007;按方案治疗（PP）分析,χ²=9.745,P=0.002)],A组与B组间及B组与C组间差异无统计意义（P>0.05）。A组和B组临床症状缓解率均高于C组（χ²=5.180,P=0.023;χ²=5.066,P=0.024）。3组间不良反应发生率差异无统计学意义（P>0.05）,各组均未出现严重不良反应。结论:雷贝拉唑/埃索美拉唑+呋喃唑酮+铋剂+阿莫西林的四联方案具有较高的Hp根除率,可改善患者临床症状,无明显的不良反应,可用于重庆农村Hp感染患者经验性治疗。更多还原

【Abstract】 Objective: To observe the eradication effect and safety in the treatment of Helicobacter pylori（Hp） based on the previous investigation and to provide theoretical basis for the selection of appropriate anti-Hp treatment scheme in rural areas of Chongqing. Methods:Two hundred and seventy patients infected with Hp from May 2015 to January 2016 in Chongqing rural areas were enrolled in this study and were randomly assigned into three groups, i.e., group A（n=90） treated with rabeprazole/esomeprazole+furazolidone+bismuthpotassium+amoxicillin, groupB（n=90）treated with lansoprazole/pantoprazole+furazolidone+bismuth potassium+amoxicillin and group C（n=90） treated with rabeprazole/esomeprazole+clarithromycin+amoxicillin. Patients in group A received rabeprazole 0.02 g/esomeprazole 0.02 g, furazolidone 0.10 g, bismuth potassium 0.20 g and amoxicillin1.0 g, twice daily for 14 days. Patients in group B received pantoprazole 0.04 g/lansoprazole 0.03 g, furazolidone 0.10 g, bismuth potassium 0.20 g and amoxicillin 1.0 g twice daily for 14 days, and patients in group C received rabeprazole 0.02 g/esomeprazole 0.02 g, clarithromycin 0.50 g and amoxicillin 1.0 g,twice daily for 14 days. Four weeks after therapy, all patients underwent ¹³C/¹⁴C test. The eradication rate, remission rate and the adverse effects of the three groups were recorded and compared. Results:The Hp eradication rate in group A was significantly higher than that in group C（P<0.05）. The remission rates of clinical symptoms in group A and B were higher than those in group C（P< 0.05）. There were no significant differences in the incidence of adverse reactions among the 3 groups（P>0.05）. Conclusion:The 14-d quadruple therapy（rabeprazole/esomeprazole combined with bismuth, furazolidone and amoxillicin） achieves satisfactory Hp eradication rates with no adverse reaction,which can be recommended as empirical therapy for Hp eradication in rural population of Chongqing.更多还原